AGLE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 lapkr. 2023 @ 23:00):

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases...

Stats
Dzisiejszy wolumen	43 238.00
Średni wolumen	59 537.00
Kapitalizacja rynkowa	48.63M
EPS	$0 ( 2024-03-07 )
Następna data zysków	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.162
ATR14	$2.39 (12.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Fairmount Funds Management Llc	Buy	406 038	Common Stock
2023-12-29	Fairmount Funds Management Llc	Sell	3 435 480	Common Stock
2023-12-22	Burrows Scott L	Buy	134 953	Common Stock
2023-12-07	Fairmount Funds Management Llc	Buy	16 667	Series B Preferred Stock
2023-11-22	Albers Jeffrey W.	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
-5.26
Last 85 transactions
Buy: 64 136 392 \| Sell: 71 129 759

Wolumen Korelacja

Długi: 0.44 (neutral)

Krótki: -0.73 (moderate negative)

Signal:(64.735) Neutral

Aeglea Bio Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
GAINL	0.987
RETA	0.975
PRVB	0.967
ULBI	0.966
RDUS	0.964
SQL	0.96
HURN	0.948
CSSE	0.946
SONN	0.945
SGMO	0.945

10 Najbardziej negatywne korelacje
BOCH	-0.967
LMRK	-0.964
SBNYP	-0.962
SHSP	-0.956
TIOA	-0.944
MSDA	-0.941
ANIK	-0.939
MSDAU	-0.938
SKYA	-0.938
QADA	-0.937

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aeglea Bio Therapeutics Korelacja - Waluta/Towar

0.01
( neutral )

0.36
( neutral )

0.04
( neutral )

-0.52
( weak negative )

Aeglea Bio Therapeutics Finanse

Annual	2022
Przychody:	$2.33M
Zysk brutto:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2022
Przychody:	$2.33M
Zysk brutto:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2021
Przychody:	$18.74M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.233

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.